# A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

> **NCT06304961** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Tozorakimab

## Key facts

- **NCT ID:** NCT06304961
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304961, "A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06304961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*